Blood system changes since recognition of transfusion-associated AIDS

Transfusion

Volumn 53, Issue 10 PART 2, 2013, Pages 2365-2374

  Epstein, Jay S ^a   Jaffe, Harold W ^b   Alter, Harvey J ^c   Klein, Harvey G ^c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTHRAX; ARTICLE; BLOOD; BLOOD SAFETY; BLOOD TRANSFUSION; CHAGAS DISEASE; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; GOVERNMENT REGULATION; HEPATITIS; HISTORY; HUMAN; LEGAL ASPECT; ORGANIZATION AND MANAGEMENT; PATHOGENICITY; PSYCHOLOGICAL ASPECT; RETROVIRUS; RETROVIRUS INFECTION; STANDARD; TRANSFUSION MEDICINE; VIROLOGY; WEST NILE FEVER; XENOTROPIC MULV RELATED VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; CREUTZFELDT-JAKOB SYNDROME; LEGISLATION AND JURISPRUDENCE; PSYCHOLOGY; RETROVIRIDAE INFECTIONS; STANDARDS; TRANSMISSION; TRENDS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTHRAX; BLOOD SAFETY; BLOOD TRANSFUSION; CHAGAS DISEASE; CREUTZFELDT-JAKOB SYNDROME; GOVERNMENT REGULATION; HEPATITIS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; RETROVIRIDAE; RETROVIRIDAE INFECTIONS; TRANSFUSION MEDICINE; WEST NILE FEVER; XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS;

EID: 84891716462     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12373     Document Type: Note

References (71)

1. Gallo R, Montagnier L. HIV's leading men. IAVI Rep 2011; 15:13-4.
2. Montagnier L. 25 years after HIV discovery: prospects for cure and vaccine. Virology 2010;397:248-54.
3. Centers for Disease Control and Prevention. Epidemiologic notes and reports pneumocystis carinii pneumonia among persons with hemophilia A. MMWR 1982;31:365-7.
4. Centers for Disease Control and Prevention. Possible transfusion- associated acquired immune deficiency syndrome (AIDS)-California. MMWR 1982;31:652-4.
5. Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. Blood 2008;112:2617-26.
6. Perkins HA, Busch MP. Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 2010;50:2080-99.
7. Schmidt PJ. Syphilis: a disease of direct transfusion. Transfusion 2001;41:1069-71.
8. Centers for Disease Control and Prevention. Current trends prevention of acquired immune deficiency syndrome (AIDS): report of inter-agency recommendations. MMWR 1983;32:101-3.
9. Leveton LB, Sox Jr HC, Stoto MA, editors. HIV and the blood supply: an analysis of crisis decision making. Washington DC: Institute of Medicine National Academy Press; 1995.
10. Smith EN, Holland PV, Holliman SM, Fuller MJ. Staff costs associated with the implementation of a comprehensive compliance program in a community blood center. Transfusion 1995;35:679-82.
11. Stein J, Besley J, Brook C, Hamill M, Klein E, Krewski D, Murphy F, Richardson M, Sirna J, Skinner M, Steiner R, van Aken P, Devine D. Risk-based decision-making for blood safety: preliminary report of consensus conference. Vox Sang 2011;101:277-81.
12. US Department of Health and Human Services. Improving Blood Safety and Supply in the U.S. 2001. [cited 2013 Aug 6]. Available from: URL: http://archive.hhs.gov/news/press/2001pres/01fsbloodsafety.html
13. Busch MP, Stramer SL. The efficiency of HIV p24 antigen screening of US blood donors: projections versus reality. Infusionsther Transfusionsmed 1998;25:5-8.
14. Ward JW, Deppe DA, Samson S, Perkins H, Holland P, Fernando L, Feorino PM, Thompson P, Kleinman S, Allen JR. Risk of human immunodeficiency virus infection from blood donors who later developed the acquired immunodeficiency syndrome. Ann Intern Med 1987;106:61-3.
15. Busch M, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. Transfusion 1991;31:4-11.
16. Centers for Disease Control and Prevention/United States Public Health ServiceWorking Group. Guidelines for counseling persons with human T-lymphotropic virus Type I (HTLV-I) and Type II (HTLV-II). Ann Intern Med 1993;118: 448-54.
17. Beeson PB. Jaundice occurring one to four months after transfusion of blood or plasma: report of seven cases. JAMA 1943;121:1332-4.
18. Seeff LB, Beebe GB, Hoofnagle JH, Norman JE, Buskell-Bales Z, Waggoner JG, Kaplowitz N, Koff RS, Petrini JL Jr, Schiff ER, Shorey J, Stanley MM. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987;316:965-70.
19. Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemia sera. JAMA 1965;191:541-6.
20. London WT, Sutnick AI, Blumberg BS. Australia antigen and acute viral hepatitis. Ann Intern Med 1969;70: 55-9.
21. Prince AM, Hargrove R, Szmuness W, Cherubin CE, Fontana BJ, Jeffries NB. Immunologic distinction between infectious and serum hepatitis. N Engl J Med 1970;282:987-91.
22. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970;1:695-98.
23. Krugman S, Giles JP, Hammond J. Infectious hepatitis: evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA 1967;200: 365-73.
24. Walsh JH, Purcell RH, Morrow AG, Chanock RM, Schmidt PJ. Posttransfusion hepatitis after open-heart operations. JAMA 1970;211:261-5.
25. Allen JG, Sayman WA. Serum hepatitis from transfusions of blood. JAMA 1962;108:1079-85.
26. Alter HJ, Holland PV, Purcell RH, Lander JJ, Feinstone SM, Morrow AG, Schmidt PJ. Posttransfusion hepatitis after exclusion of the commercial and hepatitis B antigen positive donor. Ann Intern Med 1972;77:691-9.
27. Feinstone SM, Kapikian AZ, Purcell RH. Hepatitis A: detection by immune electron microscopy of a virus-like antigen associated with acute illness. Science 1973;182: 1026-8.
28. Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975;292: 767-70.
29. Bradley DW, Maynard JE, Popper H, Cook EH, Ebert JW, McCaustland KA, Schable CA, Fields HA. Posttransfusion non-A, non-B hepatitis: physiochemical properties of two distinct agents. J Infect Dis 1983;148:254-65.
30. Feinstone SM, Mihalik KB, Kamimura J, Alter HJ, London WT, Purcell RH. Inactivation of hepatitis B virus and non-A, non-B virus by chloroform. Infect Immun 1983;4: 816-21.
31. He L-F, Alling DW, Popkin TJ, Shapiro M, Alter HJ, Purcell RH. Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis 1987;156:636-40.
32. Berman MD, Alter HJ, Ishak KG, Purcell RH, Jones EA. The chronic sequelae of non-A, non-B hepatitis. Ann Intern Med 1979;91:1-6.
33. Aach RD, Szmuness W, Mosley JW, Hollinger FB, Khan RA, Stevens CE, Edwards VM, Werch J. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: the transfusion-transmitted virus study. N Engl J Med 1981;304:989-94.
34. Alter HJ, Purcell RH, Holland PV, Alling DW, Koziol DE. The relationship of donor transaminase (ALT) to recipient hepatitis: impact on blood transfusion services. JAMA 1981;246:630-4.
35. Alter HJ. Hepatitis C virus and eliminating post-transfusion hepatitis. Nat Med 2000;6:12-4.
36. Stevens CE, Aach RD, Hollinger FB, Mosley JW, Szmuness W, Khan R, Werch R, Edwards V. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients: an analysis of the Transfusion-Transmitted Virus Study. Ann Intern Med 1984;101:733-8.
37. Koziol DE, Holland PV, Alling DW, Melpolder JC, Solomon RE, Purcel RH, Hudson LM, Shoup FJ, Krakauer H, Alter HJ. Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood. Ann Intern Med 1986;104:488-95.
38. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
39. Kuo G, Choo OL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo M, Lee WS, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M. An assay for circulating antibodies to a major etiologic virus of non-A, non-B hepatitis. Science 1989;244: 362-4.
40. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo Q-L, Kou G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-500.
41. CDC. West Nile virus activity-United States, October 10-16, 2002, and update onWest Nile virus infections in recipients of blood transfusions. MMWR 2002;51:929-31.
42. Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, Stramer SL, Stobierski MG, Signs K, Newman B, Kapoor H, Goodman JL, Chamberland ME; West Nile Virus Transmission Investigation Team. Transmission ofWest Nile virus through blood transfusion in the United States in 2002. N Engl J Med 2003;349:1236-45.
43. Mitka M. AsWest Nile virus season heats up, blood safety testing lags behind. JAMA 2003;289:2341-2.
44. Stramer SL, Fang CT, Foster GA, Wagner AG, Brodsky JP, Dodd RY. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 2005;353:451-9.
45. Busch MP, Caglioti S, Robertson EF, McAuley JD, Tobler LH, Kamel H, Linnen JM, Shyamala V, Tomasulo P, Kleinman SH. Screening the blood supply forWest Nile virus RNA by nucleic acid amplification testing. N Engl J Med 2005;353:460-7.
46. Custer B, Tomasulo PA, Murphy EL, Caglioti S, Harpool D, McEvoy P, Busch MP. Triggers for switching from minipool testing by nucleic acid technology to individual-donation nucleic acid testing forWest Nile virus: analysis of 2003 data to inform 2004 decision making. Transfusion 2004;44: 1547-54.
47. Collins SJ, Lawson VA, Masters CL. Transmissible spongiform encephalopathies. Lancet 2004;363:51-61.
48. Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science 2001;294: 1726-8.
49. Bacchetti P. Uncertainty due to model choice in variant Creutzfeldt-Jakob disease projections. Stat Med 2005;24:83-93.
50. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease (CJD) and variant Creutzfeldt-Jakob disease (vCJD) by blood and blood products. May 2010. [cited 2013 Aug 6]. Available from: URL: http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/UCM213415.pdf
51. Zou S, Fang CT, Schonberger LB. Transfusion transmission of human prion diseases. Transfus Med Rev 2008;22:58-69.
52. Kirchhoff LV, Paredes P, Lomeli-Guerrero A, Paredes-Espinoza M, Ron-Guerrero CS, Delgado-Mejia M, Pena-Munoz JG. Transfusion-associated Chagas disease (American trypanosomiasis) in Mexico: implications for transfusion medicine in the United States. Transfusion 2006;46:298-304.
53. US Department of Health and Human Services. Guidance for industry: use of serological tests to reduce the risk of transmission of Trypanosoma cruzi infection in whole blood and blood components intended for transfusion. 2010. [cited 2013 June 28]. Available from: URL: http://www.fda.gov/ biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ ucm235855.htm
54. Leiby DA, Herron RM, Read BA, Lenes BA, Stumpf RJ. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002;42:549-55.
55. Custer B, Agapova M, Bruhn R, Cusick R, Kamel H, Tomasulo P, Biswas H, Tobler L, Lee TH, Caglioti S, Busch M. Epidemiological and laboratory findings from 3 years of testing United States blood donors for Trypanosoma cruzi. Transfusion 2012;52:1901-116.
56. Cantey PT, Stramer SL, Townsend RL, Kamel H, Ofafa K, Todd CW, Currier M, Hand S, Varnado W, Dotson E, Hall C, Jett PL, Montgomery SP. The United States Trypanosoma cruzi Infection Study: evidence for vector-borne transmission of the parasite that causes Chagas disease among United States blood donors. Transfusion 2012;52: 1922-30.
57. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hauer J, McDade J, Osterholm MJ, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999;281:1735-45.
58. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2003. Morb Mortal Wkly Rep MMWR 2005;52:1.
59. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: recommendations for assessment of donor suitability and blood and blood product safety in cases of possible exposure to anthrax. October 2001. [cited 2013 June]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm076711.htm.
60. Lombardi VC, Ruscetti FW, Das Gupta J, Pfost MA, Hagen KS, Peterson DL, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold B, Dean M, Silverman RH, Mikovits JA. Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 2009;326:585-9.
61. Lo S-C, Pripuzova N, Bingjie L, Komaroff AL, Hung G-C, Wang R, Alter H. Detection of MLV-related gag gene sequences in blood of patients with chronic fatigue syndrome and healthy blood donors. Proc Natl Acad Sci U S A 2010;107:15874-9.
62. Switzer W, Jia H, Hohn O, Zheng H, Tang S, Shankar A, Bannert N, Simmons G, Hendry M, Falkenberg VR, Reeves WC, Heneine W. Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States. Retrovirology 2010;7:57.
63. Klein HG, Dodd RY, Hollinger FB, Katz LM, Kleinman S, McCleary KK, Silverman RH, Stramer SL; AABB Interorganizational Task Force on XMRV. Xenotropic murine leukemia virus-related virus (XMRV) and blood transfusion: report of the AABB interorganizational XMRV task force. Transfusion 2011;51:654-61.
64. Simmons G, Glynn SA, Komaroff AL, Mikovits JA, Tobler LH, Hackett J Jr, Tang N, Switzer WM, Heneine W, Hewlett IK, Zhao J, Lo SC, Alter HJ, Linnen JM, Gao K, Coffin JM, Kearney MF, Ruscetti FW, Pfost MA, Bethel J, Kleinman S, Holmberg JA, Busch MP; Blood XMRV Scientific Research Working Group (SRWG). Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science 2011;334:814-7.
65. Alter HJ, Mikovits JA, Switzer WM, Ruscetti FW, Lo SC, Klimas N, Komaroff AL, Montoya JG, Bateman L, Levine S, Peterson D, Levin B, Hanson MR, Genfi A, Bhat M, Zheng H, Wang R, Li B, Hung GC, Lee LL, Sameroff S, Heneine W, Coffin J, Hornig M, Lipkin WI. A multicenter blinded analysis indicates no association between chronic fatigue syndrome/myalgic encephalomyelitis and either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus. Mbio 2012;3(5) pii: e00266-12.
66. Brecher ME, Jacobs MR, Katz LM, Jacobson J, Riposo J, Carr-Greer A, Kleinman S; AABB Bacterial Contamination Task Force. Survey of methods used to detect bacterial contamination of platelet products in the United States in 2011. Transfusion 2013;53:911-8.
67. Juhl D, Baylis SA, Blümel J, Görg S, Hennig H. Seroprevalence and incidence of hepatitis E virus infection in German blood donors. Transfusion 2013. doi: 10.1111/ trf.12121.
68. Stramer SL, Linnen JM, Carrick JM, Foster GA, Krysztof DE, Zou S, Dodd RY, Tirado-Marrero LM, Hunsperger E, Santiago GA, Muñoz-Jordan JL, Tomashek KM. Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion 2012;52:1657-66.
69. Johnson ST, Van Tassell ER, Tonnetti L, Cable RG, Berardi VP, Leiby DA. Babesia microti real-time polymerase chain reaction testing of Connecticut blood donors: potential implications for screening algorithms. Transfusion 2013. doi: 10.1111/trf.12125.
70. Blajchman MA. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Clin Biol 2009;16:70-4.
71. Glynn SA, Busch MP, Dodd RY, Katz LM, Stramer SL, Klein HG, Simmons G, Kleinman SH, Shurin SB; NHLBI Emerging Infectious Disease Task Force convened November 7, 2011. Emerging infectious agents and the nation's blood supply: responding to potential threats in the 21st century. Transfusion 2013;53:438-54.